Last 6.75 GBp
Change Today 0.00 / 0.00%
Volume 10.0K
CRX On Other Exchanges
As of 11:30 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

cyprotex plc (CRX) Snapshot

6.75 GBp
Previous Close
6.75 GBp
Day High
6.75 GBp
Day Low
6.75 GBp
52 Week High
01/21/14 - 13.00 GBp
52 Week Low
04/8/14 - 5.13 GBp
Market Cap
Average Volume 10 Days
-0.0037 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for CYPROTEX PLC (CRX)

Related News

No related news articles were found.

cyprotex plc (CRX) Related Businessweek News

No Related Businessweek News Found

cyprotex plc (CRX) Details

Cyprotex PLC, together with its subsidiaries, provides in vitro and in silico absorption, distribution, metabolism, excretion, toxicity, and pharmacokinetics (ADMET and PK) services in North America, Mainland Europe, and the United Kingdom. Its ADME and PK services include in vitro metabolism, in vitro permeability, physicochemical properties, bioanalysis, protein binding, and prodrug services; and toxicology services comprise multiparametric toxicity, cardiotoxicity, customised toxicology services, 3D microtissue hepatotoxicity services, mechanistic toxicity services, in vitro drug-drug interaction assays, and genotoxicity assays. The company also provides Cloe PK, a software system that uses physiologically based pharmacokinetic in silico modeling for pharmacokinetic simulation; Cloe HIA, a physiological model for the prediction of human intestinal absorption; Cyprotex Discovery Bus, a software platform to enhance drug discovery; and various in vitro safety testing services for pharmaceutical companies developing topical therapeutics, and for the cosmetics and consumer-products industries. In addition, it offers integrated drug discovery services comprising medicinal chemistry, synthetic chemistry, computational chemistry, bioscience, arrays and libraries, and process and scale-up chemistry; and physicochemical profiling services for measurement of pKa, logP/logD, solubility, and dissolution in aqueous, solvent, biorelevant media, and in the presence of formulation additives. Cyprotex PLC has collaboration with Sygnature Discovery Limited, Sirius Analytical Limited, and Pfizer. It serves various industries, including pharmaceutical, biotechnology, cosmetic, personal care, agrochemical, chemical industries, and academia. The company was founded in 1999 and is headquartered in Macclesfield, the United Kingdom.

100 Employees
Last Reported Date: 06/5/14
Founded in 1999

cyprotex plc (CRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 229.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 136.7K GBP
Compensation as of Fiscal Year 2013.

cyprotex plc (CRX) Key Developments

Cyprotex plc Announces Expansion of Bioanalytical Capabilities

Cyprotex plc announced the expansion of their bioanalytical capabilities within the BioHub site at Alderley Park in the UK to increase its offering to both existing customers and new customers in new markets. The new instruments include a Waters Xevo G2-S QTof high resolution accurate mass spectrometer (QTof), a LabLogic Beta-Ram radiochemical detector and a Waters Atmospheric Pressure Gas Chromatography (APGC) system. This investment enables Cyprotex to improve its services to its existing pharmaceutical customers as well as unlock future potential in new markets such as the chemical and personal care markets. Assessing the metabolites formed following drug exposure is a key part of the drug development process. The Waters Xevo G2-S QTof mass spectrometer is one of the most advanced instruments for this purpose. By determining the accurate mass of the metabolites it enables more precise structural characterisation to be achieved. The new QTof can also be linked to a LabLogic Beta-Ram® radiochemical detector which complements this service allowing detection of radiochemicals and quantification of radiolabelled metabolites formed. As Cyprotex expands into the personal care and chemicals market, an ability to analyse more volatile compounds is required. The Company has therefore invested in gas chromatography which is a more appropriate platform for these types of molecules. Another key trend in the market is the preclinical development of large molecules. The QTof can analyse an extended range of molecular weights meaning the analysis of larger molecules is more achievable.

Cyprotex plc Reports Consolidated Earnings Results for the Year Ended December 31, 2013

Cyprotex plc reported consolidated earnings results for the year ended December 31, 2013. For the year, revenues were £9,768,027 compared to £8,327,274 a year ago. Operating profits was £613,146 compared to £326,069 a year ago. Loss before tax was £1,157,046 compared to profit before tax of £249,215 a year ago. Loss for the year was £796,948 compared to profit of £202,502 a year ago. Loss attributable to the owners of the parent was £796,948 compared to profit attributable to the owners of the parent of £202,502 a year ago. Loss per basic and diluted share were 0.36 pence compared to earnings per basic and diluted share of 0.09 pence a year ago. Net cash from operating activities was £1,533,179 compared to £602,864 a year ago. Purchase of property, plant and equipment was £1,169,165 compared to £291,090 a year ago. Underlying EBITDA was up 59% at £1.54 million compared to £0.97 million a year ago. Loss after tax was £0.8 million compared to profit after tax of £0.2 million a year ago, due to exceptional non-cash finance charge relating to the issue of loan notes in the year of £1.6 million.

Cyprotex plc Provides Unaudited Earnings Guidance for the Full Year Ended December 31, 2013

Cyprotex plc provided unaudited earnings guidance for the full year ended December 31, 2013. For the year, the company confirm that trading is expected to be slightly ahead of market expectations at £9.77 million, an increase of approximately 17% on the comparative period. The revenue performance is encouraging across all principal geographic markets and main service operations of high throughput ADME, customised ADME and toxicology. The company expects to report, on a pre-exceptional basis, an operating profit in the range of £750,000 to £850,000 which would represent a record operating profit for the Group. The company chose to rebrand its operations in the USA in 2013 resulting in a name change of its US subsidiary to Cyprotex US, LLC. As a consequence of this rebranding exercise the Group has fully accelerated the amortisation of its intangible asset associated with the Apredica brand leading to a one-off charge to the income statement of approximately £140,000. Adding back this accelerated charge, adjusted EBITDA is expected to be slightly ahead of market expectations, in the range £1.5 million to £1.6 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRX:LN 6.75 GBp 0.00

CRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation CRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYPROTEX PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at